Search Results
Your search for ,twO matches 12124 pages
Showing 10101 - 10150Top 5 Advances in Modern Oncology
1. Chemotherapy Cures Advanced Hodgkin Lymphoma In the first chemotherapy breakthrough for advanced cancer in adults, a four-drug combination chemotherapy regimen, called MOPP (mustargen/oncovin/procarbazine/prednisone), induced long-term remissions in over half of patients with aggressive Hodgkin ...
ASCO 50th Anniversary Poll Names the Top 5 Advances From the Past 50 Years
ASCO has announced the “Top 5 Advances in 50 Years of Modern Oncology,” based on results of worldwide voting on CancerProgress.Net—ASCO’s interactive website documenting the history of progress against cancer. The “Top 5 in 50” results identify pivotal discoveries in chemotherapy, prevention,...
AACR 2014 Cancer Progress Report Call to Action: Prioritize Federal Funding for Biomedical Research
Last month, the American Association for Cancer Research (AACR) released its 2014 Cancer Progress Report: Transforming Lives Through Research, which highlights the quickening pace of drug development and approval, especially in molecularly targeted agents, that are leading to increased numbers of...
Enhanced Benefit Shown With FOLFIRI/Ziv-Aflibercept in Subset of Patients With Metastatic Colorectal Cancer
The survival benefit demonstrated in the VELOUR study for FOLFIRI (irinotecan, fluorouracil [5-FU], leucovorin) plus ziv-aflibercept (Zaltrap) vs FOLFIRI plus placebo in metastatic colorectal cancer patients who progressed on oxaliplatin-based chemotherapy persisted beyond median survival times for ...
MSH6 Mutations May Influence Temozolomide Resistance in Treatment-Naive Gliomas Independent of MGMT Methylation
Resistance to temozolomide in glioblastoma has been thought to be largely mediated by expression of the DNA repair enzyme MGMT, although there are data suggesting a role for inactivation of MSH6 and other mismatch repair proteins. In a study reported in Clinical Cancer Research, Nguyen and...
Tumor PD-L1 mRNA Expression Associated With Improved Outcome in Breast Cancer
Inhibition of the PD-1/PD-ligand1 (PD-L1) axis has shown considerable therapeutic promise in several cancers. Tumor PD-L1 protein expression may predict response to drugs targeting this pathway, but its measurement has been limited by the lack of standardized immunohistochemical methods and...
Expert Consensus Recommends Echocardiograph as Cornerstone to Protecting Cancer Patients’ Heart Health
Patients with cancer and survivors of cancer are living longer than ever before as a result of significant advances made over the past decade. Importantly, however, cardiovascular complications of their cancer treatment may present a life-threatening issue after their cancer treatment has ended....
LIVESTRONG Narrows Finalists in ‘Big C’ Competition: Winner to Be Announced This Month
Newly launched in 2014 by LIVESTRONG, “The Big C” is a one-of-a-kind global competition to generate innovations that improve the daily quality of life for the 32.5 million people around the world living with cancer now. The competition was open to entrepreneurs, trailblazers, technology whizzes,...
Moderate Form of Male Pattern Baldness Associated With Increased Risk of Aggressive Prostate Cancer
Men with moderate pattern baldness on the front and the crown of the head at age 45 had a 40% increased risk, compared to men with no baldness at that age, of developing prostate cancer later in life, according to a study led by researchers from the National Cancer Institute (NCI) and published in...
Social Media Is Helping Me Cope With Cancer
Despite a diagnosis in August 2013 of stage III high-grade spindle cell sarcoma and subsequent disease recurrence, I’m mindful of how fortunate I am that my cancer was found before widespread metastases could take hold, making treatment futile. It was just happenstance, 2 months before, on a long...
Roswell Park Researchers Awarded Nearly $5 Million to Support Research Projects
Several faculty members at Roswell Park Cancer Institute have been awarded nearly $5 million in grant funding from public and private organizations to further their efforts to find new and better ways to detect and treat cancer and improve patients’ quality of life. The 13 awards, including two for ...
The Audacity of Courage
We have toolsWe have ghoulsBut nowhere are there more foolsThan in the rulesfrom those who govern the tools! In the bias That climbs on the shoulders To bring plausibility Through implied causality,Where is ignorance?Where is reality?Where are all the tools of Reason? ...
Genetic ‘Hotspot’ Linked to Endometrial Cancer Aggressiveness
Parents of twins often tell them apart through subtle differences such as facial expression, moles, voice tone, and gait. Similarly, physicians treating women with endometrial cancer must be able to distinguish between different versions of this disease form that, on the surface, appear the same....
Lympho-Sarcoma Treated by Radiation, Patient of Francis H. Williams, MD, Boston, 1902
One of the miracles produced by the x-ray was the relatively easy treatment of inoperable or disfiguring tumors. If not a cure, the results frequently gave the patients at least some time to look and feel normal. The young patient shown in these photographs had a remarkable response. Images such as ...
100 Years of Progress in Oncology Treatment
In his powerful 2010 best-seller, The Emperor of All Maladies: A Biography of Cancer (Scribner), Siddhartha Mukherjee, MD, chronicles the evolution of cancer from the oldest known description of the disease written on a papyrus from about 1600 BC to the present day’s understanding of the biology of ...
Choosing Wisely® Campaign Identifies Five Radiation Treatments Not for Routine Use
The American Society for Radiation Oncology (ASTRO) reported a second list of five radiation oncology treatments that should not be used routinely in clinical practice on day 1 of the Society’s 56th Annual Meeting.1 These five treatments should be discussed in depth with patients prior to being...
Effective Prevention Measures Urgently Needed to Prevent Global Cancer Crisis
Earlier this year the International Agency for Research on Cancer (IARC), an agency of the World Health Organization, launched a World Cancer Report 2014. The report, a collaboration of over 250 leading scientists from more than 40 countries, described multiple aspects of cancer research and...
Improving Treatment of Depression in Patients With Cancer: The SMaRT Oncology-2 Trial
Clinical depression is highly prevalent, associated with significant morbidity, often underrecognized, and inadequately treated in cancer patients. Professor Michael Sharpe and Jane Walker, PhD, and their colleagues’ seminal work on enhancing treatment of depression in cancer patients using a...
Failure of Cilengitide in Newly Diagnosed Glioblastoma With Methylated MGMT Promoter
Temozolomide in combination with radiation for newly diagnosed glioblastoma was approved by the U.S. Food and Drug Administration in 2005—almost 10 years ago—but we have unfortunately made little progress in improving survival for this incurable brain tumor. Despite recent completion of three...
CENTRIC Trial Shows No Benefit of Adding Cilengitide to Therapy in Glioblastoma With Methylated MGMT Promoter
In the phase III CENTRIC/European Organisation for Research and Treatment of Cancer (EORTC) 26071-22072 trial reported in The Lancet Oncology, Roger Stupp, MD, of University Hospital Zurich, and colleagues found that adding the selective αvβ3 and αvβ5 integrin inhibitor cilengitide to standard...
Cancer Survivors Face Lasting Financial Struggles Long After Treatment Ends, New Study Reports
The majority (62%) of America’s middle-income cancer survivors say they were not financially prepared for cancer diagnosis and treatment, according to a new study released by the Washington National Institute for Wellness Solutions (IWS). The study, “Insights from Survivors: Managing the Personal,...
Time to Treatment Failure Similar With Rituximab Retreatment vs Maintenance in Low–Tumor Burden Follicular Lymphoma
Maintenance rituximab (Rituxan) has been shown to improve progression-free survival vs observation in low–tumor burden follicular lymphoma. In the Eastern Cooperative Oncology Group (ECOG) E4402 Trial (RESORT), reported in the Journal of Clinical Oncology, Brad S. Kahl, MD, of the University of...
Colonoscopic Polypectomy and Predicting Cancer Risk: A Work in Progress
Colon cancer screening using colonoscopy has significantly decreased the incidence and mortality of colorectal cancer in the United States. In the National Polyp Study (NPS), colorectal cancer was prevented by removal of adenomatous polyps.1 A more recent study looking at long-term follow-up from...
Lower- vs Higher-Than-Expected Long-Term Colorectal Cancer Mortality After Removal of Lower- vs Higher-Risk Adenomas
Few data are available on long-term risk of colorectal cancer mortality after adenoma removal. In a Norwegian study reported in The New England Journal of Medicine, Magnus Løberg, MD, of the Department of Health Management and Health Economics, University of Oslo, and colleagues found that patients ...
First Approval of PD-1 Inhibitor: Pembrolizumab in Unresectable or Metastatic Melanoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On September 4, 2014, pembrolizumab (Keytruda) was granted...
Despite Growing Awareness, the Global Crisis of Untreated Cancer Pain Persists
Each day, millions of patients with cancer around the world suffer unrelieved pain because they are denied morphine, the gold standard of cancer pain control. The World Health Organization has called access to morphine a human rights issue. Not surprisingly, the crisis in unrelieved cancer pain is...
Life-Threatening Dermatologic Toxicity
A variety of life-threatening dermatologic adverse events may occur in association with cancer drug therapies. Here, we discuss the recognition and management of three types of such toxicities: type I hypersensitivity/anaphylaxis, Stevens-Johnson syndrome/toxic epidermal necrolysis, and drug rash...
Attaining the Goal of Preventing Ovarian Cancer
Fifteen years ago, David Fishman, MD, launched the National Ovarian Cancer Early Detection Program as part of the National Cancer Institute’s Early Detection Research Network. The goal of the research effort was to develop methods to accurately detect ovarian cancer while it was still confined to...
ASCO Clinical Practice Guideline: Chemotherapy and Targeted Therapy in Advanced HER2-Negative or HER2 Status–Unknown Breast Cancer
The American Society of Clinical Oncology has released a new clinical practice guideline on chemotherapy and targeted therapy for women with advanced HER2-negative or HER2 status–unknown breast cancer. The guideline is published in the Journal of Clinical Oncology.1 In formulating the consensus...
Society Announces Candidates for 2015 ASCO Election
Fourteen distinguished ASCO members have been selected by the ASCO Nominating Committee as candidates for open leadership positions within the Society for the 2015 ASCO Election. Biographical information and interviews with each candidate, as well as instructions for casting a proxy ballot, will be ...
REVEL: Winning a Questionable Race
The investigators and sponsors of the phase III REVEL trial should be congratulated and probably commiserated. In this large study, reported by Garon and colleagues in The Lancet and reviewed in this issue of The ASCO Post, 1,253 patients with advanced non–small cell lung cancer (NSCLC) were...
Early Study Finds BRCA-Mutated Pancreatic Cancer Responds to PARP Inhibition Trio
Two-thirds of patients with advanced pancreatic adenocarcinoma who harbored BRCA mutations responded to the combination of veliparib, cisplatin, and gemcitabine in a phase IB trial that is paving the way for future studies of novel poly(ADP-ribose) polymerases (PARP) inhibitors in this challenging...
Aldoxorubicin Receives FDA Orphan Drug Designations for Glioblastoma, Small Cell Lung Cancer, and Ovarian Cancer
The U.S. Food and Drug Administration has granted Orphan Drug Designations to aldoxorubicin in three indications: glioblastoma multiforme, small cell lung cancer, and ovarian cancer. Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and specifically to...
FDA Grants Orphan Drug Designation to Bivalent Vaccine for Neuroblastoma
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MabVax Therapeutics’ vaccine for the treatment of relapsed or recurrent high-risk neuroblastoma in remission or with limited residual disease after best available treatment. The bivalent vaccine is intended to elicit ...
CTNeoBC Analysis: Response to Neoadjuvant Chemotherapy Varies by Breast Tumor Subtype
Women who achieve a pathologic complete response (pCR) to neoadjuvant chemotherapy rarely have local or regional recurrence of breast cancer, but this largely depends on tumor subtype, which remained an independent predictor of locoregional recurrence when pathologic response was taken into account ...
In Ductal Carcinoma in Situ, Margin Status Need Not Dictate Reexcision
A study of 252 patients with ductal carcinoma in situ raises questions regarding the need to reexcise close margins.1 The findings were presented at a poster session during the 2014 Breast Cancer Symposium by Rachel Gentile, BS, of the Medical College of Wisconsin. The researchers evaluated data...
Pathologic Complete Response: Understanding the Subtleties
In the neoadjuvant treatment of breast cancer, the importance of achieving a pathologic complete response (pCR) varies substantially by breast cancer subtype. Patients are increasingly interested in this outcome, but it means different things to different patients, according to two breast cancer...
Managing Resistance to Targeted Agents: The Future of NSCLC Therapy
The bane of treating non–small cell lung cancer (NSCLC) patients with druggable mutations has been the development of resistance to targeted agents. New compounds are meeting the challenge of treating resistant disease, according to Fadlo R. Khuri, MD, FACP, Professor and Chair of Hematology and...
Exciting Highlights in Several Types of Lymphoma Presented at Best of ASCO
Antibody-drug conjugates are being tested against several types of lymphomas and for some of these agents, “activity is quite impressive,” Andrew M. Evens, DO, MSc, reported at the recent Best of ASCO meeting in Chicago. Dr. Evens, Professor of Medicine, Chief, Division of Hematology/Oncology, and...
Duration of Androgen-Deprivation Therapy for Patients With High-Risk Prostate Cancer
Optimal duration of androgen-deprivation therapy as part of primary therapy for prostate cancer continues to be an important question. Two well-conducted studies reported recently at the 56th Annual Meeting of the American Society for Radiation Oncology (ASTRO) provide data that can help inform...
Radiation Alone Is as Effective as and Less Toxic Than Chemoradiation for Advanced Esophageal Cancer
Radiation therapy alone was found to be as effective as chemoradiation in reducing dysphagia associated with advanced esophageal cancer in the palliative setting and was less toxic, according to results of a multinational phase III trial called the Trans-Tasman Radiation Oncology Group (TROG) 03.01 ...
Expert Point of View: Kenneth B. Roberts, MD
This is a provocative study, showing unexpected differences in acute skin reactions with conventional fractionation vs hypofractionation. Some studies have failed to show differences in acute toxicities between these two types of radiation therapy,” said Kenneth B. Roberts, MD, Professor of...
Expert Point of View: Benjamin Movsas, MD
Benjamin Movsas, MD, Chair of Radiation Oncology at Henry Ford Hospital in Detroit, served as moderator at a press conference where the two SBRT studies by Timmerman et al and Ashworth et al were reported.1,2 Dr. Movsas said that SBRT is a promising approach, noting that the therapy facilitates...
Stereotactic Body Radiation Therapy Benefits Patients With Early-Stage Inoperable or Advanced Oligometastatic Lung Cancer
The door is open for expanded use of stereotactic body radiation therapy (SBRT) in patients with inoperable early-stage lung cancer and for patients with oligometastatic stage IV non-small cell lung cancer (NSCLC), according to results of two studies presented at the 56th Annual Meeting of the...
Relevance of the Hippocratic Oath in the 21st Century
On the face of it, the idea that a code of professional conduct dating to the ancient Iron Age could possibly retain any relevance in the current era of “Big Data,” religious and cultural pluralism, trillion-dollar government budgets, and nanotechnology seems preposterous. Yet the well-publicized...
Expert Point of View: Benjamin Movsas, MD
Benjamin Movsas, MD, Chair of Radiation Oncology at Henry Ford Hospital in Detroit, served as moderator at a press conference where the two SBRT studies by Timmerman et al and Ashworth et al were reported.1,2 Dr. Movsas said that SBRT is a promising approach, noting that the therapy facilitates...
Chest Radiation Improves Survival and Intrathoracic Recurrence Rates in Extended-Stage Small Cell Lung Cancer
Thoracic radiotherapy extended progression-free survival, reduced intrathoracic recurrences, and improved overall survival at 2 years when added to prophylactic cranial irradiation in patients with extended-stage small cell lung cancer in an international randomized controlled trial.1 “Thoracic...
Updated GEM2005 Trial Confirms Benefit of Melphalan/Bortezomib Combination in Elderly Multiple Myeloma Patients
Melphalan in combination with bortezomib (Velcade) should be maintained as one of the standards of care for the treatment of elderly patients with multiple myeloma, concluded Spanish trialists reporting updated results from the GEM2005 study comparing bortezomib/melphalan/prednisone with...
Cervical Cancer Risks After Negative HPV Test Lower at 3 Years Than After Negative Pap Result
Three-year risks for cervical cancer and cervical intraepithelial neoplasia grade 3 or worse (CIN3+) were lower following a negative test for human papillomavirus (HPV) than following a negative Pap test, according to a large study comparing three cervical cancer screening strategies, HPV or Pap...
Lessons From Cancer
For a year before I was diagnosed with acute myeloid leukemia (AML) in December 2011, I had what I thought were the lingering remnants of a bad case of bronchitis. My breathing was labored, I had a chronic cough, and occasionally my voice would give out. Every time I saw my pulmonologist, I would...
